JP2004505039A - Ｃｏｐｄに付随する増悪の減少方法 - Google Patents
Ｃｏｐｄに付随する増悪の減少方法 Download PDFInfo
- Publication number
- JP2004505039A JP2004505039A JP2002515242A JP2002515242A JP2004505039A JP 2004505039 A JP2004505039 A JP 2004505039A JP 2002515242 A JP2002515242 A JP 2002515242A JP 2002515242 A JP2002515242 A JP 2002515242A JP 2004505039 A JP2004505039 A JP 2004505039A
- Authority
- JP
- Japan
- Prior art keywords
- copd
- patients
- pde4
- treatment
- exacerbation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 230000005713 exacerbation Effects 0.000 title claims description 21
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 31
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 10
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 13
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract description 12
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract description 11
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 description 19
- 229950005741 rolipram Drugs 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 15
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010044467 Isoenzymes Proteins 0.000 description 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
- 229940124630 bronchodilator Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CFBUZOUXXHZCFB-UHFFFAOYSA-N 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-cyclohexanecarboxylic acid Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940124624 oral corticosteroid Drugs 0.000 description 2
- 230000002746 orthostatic effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- MRHCSNNEUHXNIC-UHFFFAOYSA-N 9-benzylpurin-6-amine Chemical class C1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MRHCSNNEUHXNIC-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000005528 benzodioxoles Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- 230000008518 non respiratory effect Effects 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22127500P | 2000-07-27 | 2000-07-27 | |
| PCT/US2001/023542 WO2002009689A1 (en) | 2000-07-27 | 2001-07-26 | Method for reducing exacerbations associated with copd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004505039A true JP2004505039A (ja) | 2004-02-19 |
Family
ID=22827112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002515242A Withdrawn JP2004505039A (ja) | 2000-07-27 | 2001-07-26 | Ｃｏｐｄに付随する増悪の減少方法 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1320361A4 (es) |
| JP (1) | JP2004505039A (es) |
| KR (1) | KR20030019620A (es) |
| CN (1) | CN1444476A (es) |
| AR (1) | AR029984A1 (es) |
| AU (2) | AU2001279023B2 (es) |
| BR (1) | BR0112682A (es) |
| CA (1) | CA2417336A1 (es) |
| CZ (1) | CZ2003141A3 (es) |
| HU (1) | HUP0300685A3 (es) |
| IL (1) | IL153919A0 (es) |
| MX (1) | MXPA03000714A (es) |
| NO (1) | NO20030332D0 (es) |
| PL (1) | PL365612A1 (es) |
| WO (1) | WO2002009689A1 (es) |
| ZA (1) | ZA200300476B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532379A (ja) * | 2002-07-09 | 2005-10-27 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作動薬およびｐｄｅ−ｉｖ阻害剤を基本とする新規な医薬組成物 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| HRP20050399B1 (hr) | 2003-03-10 | 2013-09-30 | Takeda Gmbh | Novi postupci za dobivanje roflumilasta |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| KR102087661B1 (ko) * | 2018-07-27 | 2020-03-11 | 강원대학교산학협력단 | Ｇｅｂｒ―７ｂ 화합물을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3019A1 (fr) * | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
| SE9902937D0 (sv) * | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| AP2002002446A0 (en) * | 1999-10-29 | 2002-03-31 | Smithkline Beecham Corp | Method for administering a phosphodiesterase 4 inhibitor. |
-
2001
- 2001-07-25 AR ARP010103546A patent/AR029984A1/es not_active Application Discontinuation
- 2001-07-26 HU HU0300685A patent/HUP0300685A3/hu unknown
- 2001-07-26 EP EP01957262A patent/EP1320361A4/en not_active Withdrawn
- 2001-07-26 JP JP2002515242A patent/JP2004505039A/ja not_active Withdrawn
- 2001-07-26 IL IL15391901A patent/IL153919A0/xx unknown
- 2001-07-26 BR BR0112682-2A patent/BR0112682A/pt not_active IP Right Cessation
- 2001-07-26 CN CN01813330A patent/CN1444476A/zh active Pending
- 2001-07-26 CA CA002417336A patent/CA2417336A1/en not_active Abandoned
- 2001-07-26 AU AU2001279023A patent/AU2001279023B2/en not_active Ceased
- 2001-07-26 PL PL01365612A patent/PL365612A1/xx not_active Application Discontinuation
- 2001-07-26 AU AU7902301A patent/AU7902301A/xx active Pending
- 2001-07-26 CZ CZ2003141A patent/CZ2003141A3/cs unknown
- 2001-07-26 MX MXPA03000714A patent/MXPA03000714A/es unknown
- 2001-07-26 WO PCT/US2001/023542 patent/WO2002009689A1/en not_active Ceased
- 2001-07-26 KR KR10-2003-7001144A patent/KR20030019620A/ko not_active Withdrawn
-
2003
- 2003-01-17 ZA ZA200300476A patent/ZA200300476B/en unknown
- 2003-01-22 NO NO20030332A patent/NO20030332D0/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532379A (ja) * | 2002-07-09 | 2005-10-27 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作動薬およびｐｄｅ−ｉｖ阻害剤を基本とする新規な医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0300685A3 (en) | 2004-10-28 |
| CN1444476A (zh) | 2003-09-24 |
| AU2001279023B2 (en) | 2005-11-10 |
| KR20030019620A (ko) | 2003-03-06 |
| BR0112682A (pt) | 2003-06-24 |
| CA2417336A1 (en) | 2002-02-07 |
| NO20030332L (no) | 2003-01-22 |
| WO2002009689A1 (en) | 2002-02-07 |
| CZ2003141A3 (cs) | 2004-07-14 |
| ZA200300476B (en) | 2004-04-23 |
| IL153919A0 (en) | 2003-07-31 |
| EP1320361A1 (en) | 2003-06-25 |
| HUP0300685A2 (hu) | 2003-12-29 |
| MXPA03000714A (es) | 2003-06-04 |
| NO20030332D0 (no) | 2003-01-22 |
| EP1320361A4 (en) | 2006-04-05 |
| AR029984A1 (es) | 2003-07-23 |
| AU7902301A (en) | 2002-02-13 |
| PL365612A1 (en) | 2005-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eriksson et al. | Clinical pharmacology of thalidomide | |
| JP5819328B2 (ja) | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 | |
| Skoner | Balancing safety and efficacy in pediatric asthma management | |
| KR20160129093A (ko) | 라퀴니모드를 이용한 루푸스 신장염의 치료 | |
| JP2016196473A (ja) | ラキニモドを用いるループス関節炎の治療 | |
| US20040219137A1 (en) | Method for reducing exacerbations associated with COPD | |
| JP2004505039A (ja) | Ｃｏｐｄに付随する増悪の減少方法 | |
| AU2001279023A1 (en) | Method for reducing exacerbations associated with COPD | |
| CN118973574A (zh) | 异丁司特治疗新冠肺炎后遗症的用途 | |
| TWI242431B (en) | Pharmaceutical compositions for treating pulmonary diseases | |
| JP2003522142A (ja) | 炎症性疾患の治療法および治療用組成物 | |
| US20040214805A1 (en) | Method and compositions for treating pulmonary diseases | |
| CN112203658A (zh) | 包含卓匹非索和塞尼韦洛的组合 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| JP5421099B2 (ja) | 肺動脈性肺高血圧症の治療のためのバソペプチダーゼ阻害剤の使用 | |
| WO2025018279A1 (ja) | ヒト移植片対宿主病の治療薬およびその組合せ物 | |
| JP2005533870A (ja) | アバカビールおよびアロブジンの相乗的相互作用 | |
| TW202535397A (zh) | 給藥方案 | |
| JP2007529488A (ja) | （＋）−エリトロ−メフロキンの医薬組成物及びその使用 | |
| Freeman et al. | One you may have missed | |
| AU2004205324A1 (en) | Method and compositions for treating pulmonary diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20081007 |